The Premier Integrative Applied Neurology and Therapeutic Laser Center of Arizona

New Alzheimer’s drug shows to be non-effective against Fronto-temporal demise

NEW DEMENTIA STUDY: Namenda (memantine) is a drug used to treat Alzheimer’s Disease. This new study shows that the drug has NO effect on frontotemporal dementia which is the second most common form of dementia behind Alzheimer’s.

The best way to fight dementia is to not get it! A low sugar diet is a huge first step toward that goal.

Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial

Memantine has been used off-label to treat frontotemporal lobar degeneration (FTD). A previous 26-week open-label study suggested a transient, modest benefit on neuropsychiatric symptoms as measured by the neuropsychiatric inventory (NPI). We aimed to determine whether memantine is an effective treatment for FTD.

MethodsWe did a randomised, parallel group, double-blind, placebo-controlled trial of 20 mg memantine taken orally daily for 26 weeks in patients with FTD. Participants met Neary criteria for behavioural variant FTD (bvFTD) or semantic dementia and had characteristic brain atrophy. Use of acetylcholinesterase inhibitors was prohibited. Individuals were randomly assigned to receive either memantine or matched placebo tablets (1:1) in blocks of two and four patients. All patients and study personnel were masked to treatment assignment. Primary endpoints were the change in total NPI score and clinical global impression of change (CGIC) score after 26 weeks and were analysed by intention to treat. This study is registered with Clinicaltrials.gov, number NCT00545974.

FindingsOf 100 patients screened, 81 were randomly assigned to receive memantine (39 patients) or placebo (42 patients). Five (6%) patients discontinued, and 76 completed the 26-week treatment. Enrolment numbers were lower than planned because of many patients’ preference to take memantine or cholinesterase inhibitors off-label rather than participate in a clinical trial. Memantine treatment had no effect on either the NPI (mean difference 2·2, 95% CI −3·9 to 8·3, p=0·47) or CGIC (mean difference 0·0, −0·4 to 0·4, p=0·90) after 26 weeks of treatment. Memantine was generally well tolerated; however, patients in the memantine group had more frequent cognitive adverse events (six patients) than those in the placebo group (one).

InterpretationMemantine treatment showed no benefit in patients with FTD. These data do not support memantine use in FTD.

FundingForest Research Institute.

Correspondence to: Dr Adam L Boxer, UCSF Memory and Aging Center, Sandler Neurosciences Center, 675 Nelson Rising Lane, Suite 190, Box 1207, San Francisco, CA 94158, USA
Copyright © 2013 Elsevier Ltd. All rights reserved.

Recent Posts

Janine Crifasi, DC, CCST

Dr. Janine Crifasi, our newest team member at AZ Chiropractic Neurology, is originally from New York – which explains the accent. She attended Life Chiropractic College West and was the Centennial class’s Most Outstanding Graduate. She practiced in the Bay Area until moving closer to family to raise her son who is attending college.

Dr. Janine is committed to learning and educating people to change their awareness about their bodies’ potential and empowering them with unique methods of retraining their brains to maximize their quality of life through neuroplasticity. Her passion to help others puts her patients at ease and makes her a highly sought-after community speaker. Prior to coming to Chandler, she owned a center specializing in kids with learning disabilities and served as the northeast clinical director of a functional neurology practice, overseeing several functional neurology clinics. 

She has completed her post-doctoral clinical neuroscience studies in Functional Neurology through the Carrick Institute for Graduate Studies and has successfully completed the clinical exam and is now board eligible for the written portion. She is a Board Certified Doctor of Chiropractic for over 26 years. She has received additional extensive training in Spinal Trauma, and the Activator Method, and has a certification in Postural Neurology. 

In an effort to better serve her patients, Dr. Crifasi completed postdoctoral specialty training in blood chemistry, thyroid chemistry, brain chemistry, neuro-immune, and neuro-endocrine functional medicine. This knowledge of the brain-gut axis, and the mechanisms that impact our health, allow her to provide patients with easily implemented modifications enhancing improved lifestyle and nutraceutical recommendations as needed.